Roche ($ROG) and Inovio Pharmaceuticals ($INO) had hoped to develop immunotherapies to treat prostate cancer and hepatitis B when they first partnered in 2013. But now that dream is officially dead as Roche has returned the second of two candidates and discontinued its partnership with Inovio.
{iframe}http://www.fiercebiotech.com/biotech/roche-returns-second-inovio-candidate-ends-immunotherapy-deal{/iframe}